Clinical Research Directory

Inclusion Criteria: * Participants who have provided voluntary written consent for participation in this clinical study * Participants to whom the rules for complying with this clinical study have been adequately explained, and who intend to and can comply with these rules * Participants aged greater than or equal to (\>=) 20 years at the time of informed consent * Participants with adequate function of major organs * Participants with Performance Status score of 0 to 1 established by the Eastern Cooperative Oncology Group (ECOG) * Participants who are expected to survive for 3 months or longer after starting administration of the investigational drug * Washout period required from the end of prior treatment to the first administration of study drug * Participants who agree to submit blood samples prior and during study treatment for progressive disease (PD) markers. Inclusion Criteria (Part 2 only): * Measurable disease meeting the following criteria: 1. At least 1 lesion of \>=1.0 centimeter (cm) in the longest diameter for a non-lymph node or \>=1.5 cm in the short-axis diameter for a lymph node that is serially measurable according to response evaluation criteria in solid tumours (RECIST) 1.1 using computerized tomography/magnetic resonance imaging (CT/MRI). 2. Lesions that have had external beam radiotherapy (EBRT) or locoregional therapies such as radiofrequency (RF) ablation must show evidence of progressive disease to be deemed a target lesion. Exclusion Criteria: * Medical history of clinically significant cardiovascular impairment * Serious concomitant systemic infection requiring medical treatment (including bacterial infection and fungal infection) * Participants who test positive for human immunodeficiency virus (HIV antibody) * Active viral hepatitis (B or C) as demonstrated by positive serology or requiring treatment hepatitis B surface antigen (HBsAg), anti-hepatitis B surface antibody (anti-HBs)/hepatitis B core antibody (HBcAb) and anti-hepatitis C virus (HCV) antibody test. * Effusion requiring drainage * Participants whose toxicity of previous treatment has not recovered to Grade 1 or lower (except for alopecia and hemoglobin) * Other active malignancy * Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin \[ß-hCG\] or human chorionic gonadotropin \[hCG\]). * Women of childbearing potential or men of impregnate potential who don't agree that both the participant and his/her partner will use a medically effective method for contraception during the study and after study drug discontinuation (male; 90 days, female; 60 days) * Known intolerance to the study drug or any of the excipients * Any medical or other condition that in the opinion of the investigator(s) would preclude the participant's participation in the study * Scheduled for surgery during the study * Diagnosed with meningeal carcinomatosis * Participants with brain or subdural metastases are not eligible.